Penpulimab

DRUG19 trials

Sponsors

Peking Union Medical College Hospital, Akeso, Sichuan Cancer Hospital and Research Institute, Fudan University, The First Affiliated Hospital with Nanjing Medical University

Conditions

Advanced Malignant NeoplasmAdvanced Solid TumorsAnlotinibBreast CancerColorectal AdenocarcinomaColorectal CancerDiffuse Large B Cell LymphomaEGFR Sensitive Mutation

Phase 1

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

TerminatedNCT06297642

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignant Neoplasm

Start: 2024-05-24End: 2024-07-31Updated: 2024-08-06

AK129 Combination Therapy for Advanced Solid Tumors

RecruitingNCT06943820

AkesoAdvanced Solid Tumors, Colorectal Adenocarcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) +1

Start: 2025-05-21End: 2028-05-31Target: 230Updated: 2025-06-03

JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

Not yet recruitingNCT07075419

West China HospitalRefractory Hepatocellular Carcinoma

Start: 2025-08-01End: 2027-08-01Target: 10Updated: 2025-07-20

Phase 2

Anlotinib or Penpulimab in Combination With RAI for DTC

Peking Union Medical College HospitalThyroid Cancer

Start: 2021-09-15End: 2024-07-20Target: 42Updated: 2022-01-28

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003

Peking Union Medical College HospitalColorectal Cancer

Start: 2021-11-05End: 2023-08-23Target: 32Updated: 2022-03-08

A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer

Sichuan Cancer Hospital and Research InstituteGynecological Cancer

Start: 2022-05-10End: 2025-12-31Target: 86Updated: 2023-12-27

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

RecruitingNCT05229003

Fudan UniversityMetastatic Colorectal Cancer

Start: 2022-03-09End: 2025-12-31Target: 44Updated: 2024-07-03

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma

Not yet recruitingNCT05347641

The First Affiliated Hospital with Nanjing Medical UniversityPrimary Central Nervous System Lymphoma

Start: 2022-06-01End: 2029-06-01Target: 23Updated: 2022-04-26

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Peking University Third HospitalNon-Small Cell Lung Cancer

Start: 2022-09-12End: 2024-10-15Target: 32Updated: 2022-08-03

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

CompletedNCT05493995

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPancreatic Neoplasms

Start: 2022-07-21End: 2024-05-01Updated: 2024-05-09

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

RecruitingNCT05576480

Ruijin HospitalLocally Advanced, Rectal Cancer

Start: 2023-02-06End: 2026-12-31Target: 55Updated: 2025-08-28

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

West China HospitalBreast Cancer

Start: 2023-03-01End: 2024-08-31Target: 20Updated: 2023-02-13

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Peking Union Medical College HospitalParaganglioma, Malignant, Pheochromocytoma Malignant, Pheochromocytoma, Metastatic

Start: 2023-04-01End: 2025-03-01Target: 5Updated: 2023-06-02

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

RecruitingNCT06051851

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPancreatic Adenocarcinoma Metastatic

Start: 2023-07-01End: 2026-07-01Target: 177Updated: 2023-09-25

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruitingNCT06516978

The First Affiliated Hospital with Nanjing Medical UniversityDiffuse Large B Cell Lymphoma

Start: 2024-10-01End: 2029-04-01Target: 528Updated: 2024-07-24

Phase 3

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruitingNCT04974398

AkesoNasopharyngeal Carcinoma

Start: 2021-08-16End: 2026-12-23Updated: 2025-04-13

A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

RecruitingNCT05244642

AkesoHodgkin Disease Lymphoma

Start: 2022-02-15End: 2026-03-30Target: 60Updated: 2022-02-17

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Not yet recruitingNCT06048315

Degan LuAnlotinib, EGFR Sensitive Mutation, Lung Cancer +2

Start: 2023-09-30End: 2026-09-30Target: 52Updated: 2023-09-21

Unknown Phase

Penpulimab in Maintenance Therapy in Lymphoma

Start: 2023-03-01End: 2025-03-31Target: 167Updated: 2023-01-11

Related Papers

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial.

2026-02-11

Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: A multi-centered, randomized controlled trial (RCT-PAAG).

Journal of Clinical Oncology2026-01-10

A phase II study of anlotinib plus penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Results from ALTER-GO-020 trial.

Journal of Clinical Oncology2025-05-281 citations

An exploratory clinical study investigating the neoadjuvant treatment of HER2-low expressing, stage II-III breast cancer with disitamab vedotin combined with penpulimab (RCVDBCIIR005).

Journal of Clinical Oncology2025-05-28

Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)

Cancer Research2025-04-255 citations

Updated survival results of ZL-IRIAN: Irinotecan plus anlotinib or in combination with penpulimab as second-line treatment of metastatic colorectal cancer.

Journal of Clinical Oncology2025-01-27

Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial

Signal Transduction and Targeted Therapy2024-12-127 citations

A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma

Blood2024-11-05

First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial.

2024-06-0719 citations

Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

Journal of Clinical Oncology2024-06-01

Irinotecan plus anlotinib or further in combination with penpulimab as second-line treatment of metastatic colorectal cancer (ZL-IRIAN).

Journal of Clinical Oncology2024-06-01

Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.

Journal of Clinical Oncology2024-06-01

P1145: PRELIMINARY RESULTS OF PENPULIMAB COMBINED WITH RMA(RITUXIMAB, METHOTREXATE, AND CYTARABINE) FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

HemaSphere2023-08-01

Preliminary results of penpulimab combined with RMA (rituximab, methotrexate, and cytarabine) for newly diagnosed primary central nervous system lymphoma (PCNSL)

Hematological Oncology2023-06-01

Preliminary Results of Penpulimab Combined with RMA (rituximab, methotrexate, and cytarabine) for Newly Diagnosed Primary Central Nervous System Lymphoma

Blood2022-11-15